E
Editas Medicine D
D
EDIT
1.96500
USD
-0.21
(-9.45%)
مغلق
حجم التداول
59,122
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
164,495,768
الأخبار المقالات
العنوان: Editas Medicine
القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.